

Supplementary Table S3: Prognostic value of OPG in ER positive breast cancer among individual datasets and the respective dataset characteristics (sorted according to univariate HR)

prognostic effect	dataset	HR Uni-Cox	95% CI lower	95% CI upper	P-Value	samples with follow up	% high OPG	type of adjuvant treatment	% without systemic therapy	% endocrine treatment	% chemotherapy	% Age up to 50 yr	% T1	% LNN	% G3	% Luminal-B (Hugh et al.)	% Pgr- negative	Array platform	Outcome (DMFS vs RFS)	% events at 5yr
yes	London	0.26	0.11	0.62	0.26	85	78%	endocrine	0%	100%	0%	5%	n.a.	34%	22%	22%	21%	U133Plus	RFS	15%
yes	Mainz	0.34	0.15	0.78	0.34	164	52%	untreated	100%	0%	0%	23%	n.a.	100%	9%	42%	21%	U133A	DMFS	12%
yes	BIG1-98	0.39	0.10	1.52	0.39	52	83%	mixed	0%	63%	37%	6%	n.a.	38%	33%	19%	21%	U133Plus	DMFS	19%
yes	Rotterdam	0.47	0.25	0.86	0.47	208	26%	untreated	100%	0%	0%	43%	56%	100%	63%	55%	38%	U133A	DMFS	30%
yes	TransBIG	0.47	0.27	0.81	0.47	132	53%	untreated	100%	0%	0%	68%	6%	100%	25%	41%	17%	U133A	RFS	27%
yes	Oxford-Tamoxifen	0.48	0.21	1.08	0.48	106	41%	endocrine	0%	100%	0%	14%	n.a.	63%	17%	49%	25%	U133A	RFS	20%
small	Veridex-Tam	0.53	0.19	1.47	0.53	135	41%	endocrine	0%	100%	0%	n.a.	n.a.	100%	n.a.	44%	27%	U133A	DMFS	9%
no	Stockholm	0.74	0.28	1.96	0.74	122	23%	mixed	11%	61%	n.a.	n.a.	n.a.	n.a.	31%	62%	43%	U133A	RFS	19%
no	San Francisco	0.77	0.36	1.64	0.77	78	50%	chemo	9%	45%	46%	44%	3%	44%	58%	53%	32%	U133A	DMFS	32%
no	Uppsala	0.79	0.43	1.43	0.79	199	21%	mixed	57%	31%	n.a.	18%	n.a.	67%	12%	45%	30%	U133A	RFS	26%
no	IPC	0.85	0.45	1.59	0.85	136	64%	n.a.	n.a.	n.a.	n.a.	34%	26%	43%	28%	46%	12%	U133Plus	DMFS	22%
no	Oxford-Untreated	0.86	0.23	3.13	0.86	45	27%	untreated	100%	0%	0%	42%	25%	100%	25%	56%	24%	U133A	RFS	18%
no	Boston_2	0.87	0.09	8.33	0.87	68	78%	chemo	0%	33%	67%	49%	n.a.	47%	32%	29%	25%	U133Plus	RFS	6%
no	IPC_HER2	0.90	0.09	9.09	0.90	10	80%	n.a.	n.a.	n.a.	n.a.	30%	13%	22%	50%	80%	50%	U133Plus	DMFS	40%
no	New York	0.93	0.28	3.13	0.93	45	36%	chemo	0%	17%	83%	40%	n.a.	29%	n.a.	69%	40%	U133A	DMFS	16%
no	SET2	1.02	0.45	2.27	1.02	183	15%	endocrine	0%	100%	0%	n.a.	n.a.	58%	n.a.	49%	42%	U133A	RFS	14%
no	London-2	1.03	0.33	3.23	1.03	73	48%	endocrine	0%	100%	0%	5%	n.a.	52%	39%	32%	16%	U133Plus	RFS	11%
no	SET1	1.12	0.45	2.86	1.12	100	41%	endocrine	0%	100%	0%	n.a.	n.a.	66%	n.a.	45%	25%	U133A	DMFS	14%